Biopharmaceutical heavyweight Halozyme Therapeutics Inc. announced Wednesday it will acquire fellow biotech innovator Elektrofi Inc. in a deal valued at up to $900 million, a move set to reshape the future of drug delivery technologies.

Deal Structure and Financials

The agreement calls for an upfront payment of $750 million, with up to three additional milestone payments of $50 million each, triggered by regulatory approvals for different products. Halozyme said it will finance the transaction using existing cash reserves and its credit facility.

Technology at the Center

Halozyme specializes in solutions designed to streamline the delivery of injected drugs and fluids, a growing need in modern medicine. Elektrofi, meanwhile, brings to the table its Hypercon platform, described as a “breakthrough” technology that enables ultra-high protein concentrations to be injected with ease.

The innovation allows patients to receive the same dosage with smaller injection volumes, paving the way for more at-home delivery options and greater convenience.

“This acquisition marks a pivotal step in Halozyme’s evolution,” said Helen Torley, Halozyme’s CEO and president. “With Elektrofi’s Hypercon technology, we are broadening our drug delivery portfolio and positioning Halozyme for sustained growth through licensing and royalties.”

Strategic Expansion

The deal significantly bolsters Halozyme’s drug delivery technology pipeline, adding a scalable licensing model with what the company called “compelling expansion opportunities.”

For Elektrofi, the merger represents a chance to supercharge its mission. “Since our founding, we have been committed to revolutionizing the delivery of biologic therapies,” said Chase Coffman, Elektrofi’s CEO and co-founder. “Halozyme’s proven expertise will accelerate our commercialization strategy and help bring Hypercon to more patients worldwide.”

Closing Timeline and Legal Teams

The acquisition is expected to close in the fourth quarter of 2025, subject to regulatory review and customary conditions.

Halozyme is represented by Weil Gotshal & Manges LLP, while Elektrofi is advised by a Morgan Lewis & Bockius LLP team that includes partners Russell Franklin, Mike Conza, and Andrew Haupt.

The full Weil legal team details were not immediately available.

With this deal, Halozyme isn’t just buying a company—it’s buying the future of injectable medicine, one concentrated dose at a time.